Patrick Squiban

1.4k total citations
33 papers, 970 citations indexed

About

Patrick Squiban is a scholar working on Immunology, Genetics and Molecular Biology. According to data from OpenAlex, Patrick Squiban has authored 33 papers receiving a total of 970 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Immunology, 12 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Patrick Squiban's work include Immunotherapy and Immune Responses (14 papers), Virus-based gene therapy research (12 papers) and Immune Cell Function and Interaction (8 papers). Patrick Squiban is often cited by papers focused on Immunotherapy and Immune Responses (14 papers), Virus-based gene therapy research (12 papers) and Immune Cell Function and Interaction (8 papers). Patrick Squiban collaborates with scholars based in France, United States and Switzerland. Patrick Squiban's co-authors include Bruce Acres, Nadine Bizouarne, Philippe Slos, Stéphane Paul, Elisabeth Erhardtsen, S Glazer, L. Jeffers, Rikke Bech, Ulla Hedner and Margaret Liu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Patrick Squiban

32 papers receiving 938 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Patrick Squiban France	15	452	322	296	284	154	33	970
Claude Baillou France	20	467 1.0×	449 1.4×	243 0.8×	196 0.7×	442 2.9×	56	1.3k
Deanna M. Grote United States	13	698 1.5×	212 0.7×	546 1.8×	365 1.3×	86 0.6×	23	1.4k
L Gemmell United States	9	523 1.2×	238 0.7×	204 0.7×	112 0.4×	230 1.5×	10	995
Marna Williams United States	15	897 2.0×	249 0.8×	529 1.8×	195 0.7×	113 0.7×	21	1.6k
Reuben Benjamin United Kingdom	19	295 0.7×	374 1.2×	498 1.7×	252 0.9×	168 1.1×	43	1.1k
Yuya Nagai Japan	11	433 1.0×	252 0.8×	226 0.8×	66 0.2×	125 0.8×	43	853
Todd Meyer United States	16	277 0.6×	308 1.0×	252 0.9×	86 0.3×	319 2.1×	45	1.1k
Dário Ligeiro Portugal	17	440 1.0×	371 1.2×	134 0.5×	57 0.2×	108 0.7×	47	895
Mercedes Porosnicu United States	17	201 0.4×	287 0.9×	276 0.9×	354 1.2×	80 0.5×	50	1.0k
A. Bohbot France	16	647 1.4×	362 1.1×	141 0.5×	72 0.3×	215 1.4×	40	1.1k

Countries citing papers authored by Patrick Squiban

Since Specialization

Citations

This map shows the geographic impact of Patrick Squiban's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Squiban with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Squiban more than expected).

Fields of papers citing papers by Patrick Squiban

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Squiban. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Squiban. The network helps show where Patrick Squiban may publish in the future.

Co-authorship network of co-authors of Patrick Squiban

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Squiban. A scholar is included among the top collaborators of Patrick Squiban based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Squiban. Patrick Squiban is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Senellart, Hélène, Jaafar Bennouna, Nicolás Isambert, et al.. (2012). Phase I safety and tolerability of once daily oral afatinib (A) in combination with docetaxel (D) in patients (pts) with relapsed or refractory advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). e13010–e13010. 2 indexed citations

Braza, Mounia S., Anouk Caraux, Thérèse Rousset, et al.. (2009). γδ T Lymphocytes Count Is Normal and Expandable in Peripheral Blood of Patients with Follicular Lymphoma, Whereas It Is Decreased in Tumor Lymph Nodes Compared with Inflammatory Lymph Nodes. The Journal of Immunology. 184(1). 134–140. 15 indexed citations

Laurent, Guy, Philippe Solal‐Céligny, Pierre Soubeyran, et al.. (2009). Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.. Blood. 114(22). 1649–1649. 6 indexed citations

Benson, Don, Craig C. Hofmeister, Swaminathan P. Iyer, et al.. (2009). Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.. Blood. 114(22). 2880–2880. 1 indexed citations

Benson, Don, Courtney E. Bakan, Shuhong Zhang, et al.. (2009). IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.. Blood. 114(22). 3870–3870. 3 indexed citations

Dreicer, Robert, Walter M. Stadler, F. R. Ahmann, et al.. (2008). MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Investigational New Drugs. 27(4). 379–386. 58 indexed citations

Squiban, Patrick, Emmanuelle Bompas, Jaafar Bennouna, et al.. (2007). V{gamma}9V{delta}2 T ({gamma}{delta}) lymphocytes: a promising approach for immunotherapy of solid tumors. 25. 3064.

Fardeau, Michel, Serge Braun, Norma B. Romero, et al.. (2005). A propos d'un essai de Phase I de thérapie génique effectué avec un plasmide contenant l'intégralité du gène dystrophine dans la Myopathie de Duchenne/Becker. Journal de la Société de Biologie. 199(1). 29–32. 7 indexed citations

Liu, Margaret, Bruce Acres, Jean‐Marc Balloul, et al.. (2004). Gene-based vaccines and immunotherapeutics. Proceedings of the National Academy of Sciences. 101(suppl_2). 14567–14571. 137 indexed citations

10.

Pantuck, Allan J., Arndt van Ophoven, Barbara J. Gitlitz, et al.. (2004). Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-Positive Patients With Advanced Prostate Cancer. Journal of Immunotherapy. 27(3). 240–253. 57 indexed citations

11.

Dreicer, Robert, et al.. (2004). 577. MVA-MUC1-IL2 Vaccine Immunotherapy for Patients Post-Prostatectomy with Rising PSA and No Evident Metastases. Molecular Therapy. 9. S218–S218. 1 indexed citations

12.

Acres, Bruce, et al.. (2004). Therapeutic cancer vaccines.. PubMed. 6(1). 40–7. 13 indexed citations

13.

Rochlitz, Christoph, Robert A. Figlin, Patrick Squiban, et al.. (2003). Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer. The Journal of Gene Medicine. 5(8). 690–699. 139 indexed citations

14.

Khorana, Alok A., Joseph D. Rosenblatt, Deepak M. Sahasrabudhe, et al.. (2003). A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Therapy. 10(4). 251–259. 49 indexed citations

15.

Griscelli, Frank, Paule Opolon, Patrick Saulnier, et al.. (2003). Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Therapy. 10(5). 386–395. 29 indexed citations

16.

Romero, Norma B., Olivier Benvéniste, C. Payán, et al.. (2002). Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Neuromuscular Disorders. 12. S45–S48. 31 indexed citations

17.

Rochlitz, Christoph, Brigitte Dréno, Peter Jantscheff, et al.. (2002). Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels. Cancer Gene Therapy. 9(3). 289–295. 27 indexed citations

18.

Thioudellet, Christine, Stéphane Blot, Patrick Squiban, Michel Fardeau, & Serge Braun. (2002). Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Neuromuscular Disorders. 12. S49–S51. 14 indexed citations

19.

Tartour, Éric, Majid Mehtali, Xavier Sastre‐Garau, et al.. (2000). Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings. British Journal of Cancer. 83(11). 1454–1461. 19 indexed citations

20.

Jeffers, L., Elisabeth Erhardtsen, S Glazer, et al.. (1997). Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology. 113(6). 1930–1937. 188 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact